SELLAS Life Sciences Group, Inc. (SLS) Misses Q3 EPS by 35c

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q3 EPS of ($0.33), $0.35 worse than the analyst estimate of $0.02.

For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Evolution Petroleum launches stock offering to fund Permian Basin deal
• Halozyme adds biotech executive Appelhans to its board